Please find all related articles below.
EPHA welcomes the Commission’s publication of comprehensive consultation guidelines. Smart regulation should mean fair and citizen-centred policy making that brings tangible benefits to the citizens of Europe and improves their quality of life. This involves greater use of evidence-based impact assessment and improving the consultation process.
The aim of the guidelines should be to ensure transparency and representativeness. Publishing consultation responses, as well as explanations (...)
Below you can find EPHA’s response to the public consultation on the mid-term review of the Europe 2020 Strategy. EPHA believes that the Europe 2020 Strategy should be revised in order to better serve the public health interests of Europeans. Current targets do not invest enough in sustainable development despite its potential to create economic surplus in addition to social benefits. EPHA advocates the addition of more health targets in the Europe 2020 Strategy as well as more (...)
October 22th 2014, Brussels – The NGO signatories of this statement wholeheartedly welcome the announcement of the reversal of the decision by President-elect Jean-Claude Juncker to move the competence for pharmaceutical and medical devices to the enterprise directorate (1).
Following negotiations within the European Parliament and concerns expressed by a number of member states, President-elect Juncker stated today that the "responsibility for medicines and pharmaceutical products (...)
Health is a fundamental universal right and access to medicines is part of it. The EU and its Member States are committed to universal and equitable access to healthcare. Nevertheless, millions of European patients suffer from the lack of affordability of many life-saving medicines across Europe.
Download the event’s invitation
* See the event’s poster
An event under the auspices of MEPs Nessa CHILDERS (S&D, IE), Beatriz BECERRA BASTERRECHEA (ALDE, ES), Kostas (...)
14 October 2014, Brussels - . The European Commission’s High Level Group on Administrative Burdens (1), chaired by Dr Edmund Stoiber, has drawn severe criticism from 4 of a total of 15 Members (2) for its final report (3) pushing an outdated, deregulatory agenda.
Almost one third of ‘Stoiber group’ members oppose biased final report
The views of members representing trade unions, environmental groups, consumer organisations and health groups are presented in a (...)
Eurochild, with the help of its member organisations and partners, carried out an analysis of the 2014 National Reform Programmes (NRPs) of EU Member States. Respondents from 17 EU Member States (MS) provided information about the extent to which child poverty and social exclusion are addressed in the 2014 NRPs and National Social Reports.
The analysis of the responses provides an EU-wide overview of the commitment to fight child poverty and social exclusion. Despite a slight increase in (...)
October 10th 2014, Brussels – According to statements by both the S&D (1) and Green Groups (2) yesterday, it seems likely that President-elect Jean-Claude Juncker is intending to soften his decision to move pharmaceutical policy from the health portfolio to enterprise. EPHA welcomes this news as a step in the right direction and a possible cause for celebration for the European Parliament (3) and the public health community (4).
“I would like to applaud President-elect (...)
8th October 2014, Brussels - With regard to the planned transfer of the competence for medicinal products and health technologies from the health portfolio to the enterprise one (#Pharma4Health campaign), we would like to inform you that the Conference of the Presidents of the European Parliament (composed of the President of the European Parliament, Martin Schulz and the leaders of the political groups) will meet tomorrow on 9th October (Thursday).
Dear EPHA Members,
We would like to (...)
1 October 2014, Brussels - By European Parliament standards, Commissioner-designate Vytenis Andriukaitis’ performance could be judged to be “satisfactory”. He showed his commitment to protect European citizens’ health and well-being, and improve underlying determinants of health and physical environment. Now we will really have to see how he intends to turn words into concrete action. He was very outspoken on the issues of prevention, promotion and protection of (...)
September 29 2014, Brussels - When questioning the EU Commissioners-designate this week, Members of the European Parliament (MEPs) should reject the decision by Jean-Claude Juncker, the European Commission President-elect, to move pharmaceutical policy from the health to the enterprise portfolio (1). The main driver of EU policies concerning pharmaceuticals and health technologies should be promoting and protecting health and patient safety, not simply boosting the competitiveness of the (...)